Denosumab for the treatment of osteoporosis.

ABSTRACT:

Introduction

Low trauma fractures due to osteoporosis are a major health concern worldwide. Despite the availability of many therapeutic compounds to reduce fracture risk, osteoporosis remains undertreated and the burden of osteoporotic fractures remains high. Denosumab is a novel agent that acts to reduce bone turnover, improve bone mineral density, and reduce fracture risk, offering a favorable efficacy and safety profile.

Areas covered

This review covers the pharmacology and major clinical trials with extension/post-marketing follow-up, including trials for all FDA-approved indications of denosumab to date.

Expert opinion

Denosumab is an efficacious and safe osteoporosis treatment option, with current data from up to 8 years of continued use showing continued impro

SUBMITTER: Zaheer S 

PROVIDER: S-EPMC4480604 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature